På grund af muligheden for TAGVHD (Transfusion Associated Graft Versus Host Disease), bør patienter, der er blevet behandlet med MabCampath, modtage bestrålede blodprodukter.
Because of the potential for Transfusion Associated Graft Versus Host Disease (TAGVHD) it is recommended that patients who have been treated with MabCampath receive irradiated blood products.